Back to Search Start Over

Genetic modifiers in carriers of repeat expansions in the C9ORF72 gene.

Authors :
van Blitterswijk M
Mullen B
Wojtas A
Heckman MG
Diehl NN
Baker MC
DeJesus-Hernandez M
Brown PH
Murray ME
Hsiung GY
Stewart H
Karydas AM
Finger E
Kertesz A
Bigio EH
Weintraub S
Mesulam M
Hatanpaa KJ
White CL 3rd
Neumann M
Strong MJ
Beach TG
Wszolek ZK
Lippa C
Caselli R
Petrucelli L
Josephs KA
Parisi JE
Knopman DS
Petersen RC
Mackenzie IR
Seeley WW
Grinberg LT
Miller BL
Boylan KB
Graff-Radford NR
Boeve BF
Dickson DW
Rademakers R
Source :
Molecular neurodegeneration [Mol Neurodegener] 2014 Sep 20; Vol. 9, pp. 38. Date of Electronic Publication: 2014 Sep 20.
Publication Year :
2014

Abstract

Background: Hexanucleotide repeat expansions in chromosome 9 open reading frame 72 (C9ORF72) are causative for frontotemporal dementia (FTD) and motor neuron disease (MND). Substantial phenotypic heterogeneity has been described in patients with these expansions. We set out to identify genetic modifiers of disease risk, age at onset, and survival after onset that may contribute to this clinical variability.<br />Results: We examined a cohort of 330 C9ORF72 expansion carriers and 374 controls. In these individuals, we assessed variants previously implicated in FTD and/or MND; 36 variants were included in our analysis. After adjustment for multiple testing, our analysis revealed three variants significantly associated with age at onset (rs7018487 [UBAP1; p-value = 0.003], rs6052771 [PRNP; p-value = 0.003], and rs7403881 [MT-Ie; p-value = 0.003]), and six variants significantly associated with survival after onset (rs5848 [GRN; p-value = 0.001], rs7403881 [MT-Ie; p-value = 0.001], rs13268953 [ELP3; p-value = 0.003], the epsilon 4 allele [APOE; p-value = 0.004], rs12608932 [UNC13A; p-value = 0.003], and rs1800435 [ALAD; p-value = 0.003]).<br />Conclusions: Variants identified through this study were previously reported to be involved in FTD and/or MND, but we are the first to describe their effects as potential disease modifiers in the presence of a clear pathogenic mutation (i.e. C9ORF72 repeat expansion). Although validation of our findings is necessary, these variants highlight the importance of protein degradation, antioxidant defense and RNA-processing pathways, and additionally, they are promising targets for the development of therapeutic strategies and prognostic tests.

Details

Language :
English
ISSN :
1750-1326
Volume :
9
Database :
MEDLINE
Journal :
Molecular neurodegeneration
Publication Type :
Academic Journal
Accession number :
25239657
Full Text :
https://doi.org/10.1186/1750-1326-9-38